Hyperuricemia / Gout

Gout
Wayne Blount, MD, MPH
http://www.fpm.emory.edu/

Crystal-Induced Arthritis
Gerald F. Falasca, M.D., Johnson City, TN
http://www.etsu.edu/

Drug Therapy of Gout
http://www.epcc.edu/

Tumor Lysis Syndrome
Sandy Kelly
https://hci-portal.hci.utah.edu/

Diagnosis and Management of Gout
Valerie Berger, M.D.
http://intmedweb.wfubmc.edu/

Formation of PRPP: Phosphoribose pyrophosphate
Robert Lyons
http://open.umich.edu

Gout
Victoria Hackney
http://a-s.clayton.edu/

Case Study
Monique Quiroz, Mike Pehl, Andrew Ho
http://instructional1.calstatela.edu/

Joints (arthritis) – Rheumatoid arthritis
http://www.itc.csmd.edu/

Gout
Dawn Hyman
http://www1.broward.edu/


600 Published articles free access

1. Rhazes' prescriptions in treatment of gout.
2. Current management of gout.
3. Epidemiological study on hyperuricemia and gout in Uygur population in Turpan area of Xinjiang.
4. Was true gout? New interpretations of the skeletal disease(s) of the Medici family.
5. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
6. Polymorphisms in the presumptive promoter region of the SLC2A9 gene are associated with gout in a Chinese male population.
7. Association between gout and all-cause as well as cardiovascular mortality: a systematic review.
8. Coronary artery bypass grafting in a patient with gout arthritis.
9. Gout and the risk for incident heart failure and systolic dysfunction.
10. African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
11. Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial.
12. Tophaceous gout in the cervical spine.
13. Spinal tophaceous gout.
14. Images in clinical medicine. Tophaceous gout.
15. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study.
16. Intrabony tibial tophi in chronic gout.
17. Neutrophil extracellular trap formation is associated with IL-1β and autophagy-related signaling in gout.
18. MR imaging of tophaceous gout revisited.
19. The role of the NLRP3 inflammasome in gout.
20. Imaging in gout--what can we learn from MRI, CT, DECT and US?
21. Gout, genetics and ABC transporters.
22. The year in gout - 2010-2011.
23. Images in clinical medicine. Gout nodulosis.
24. Multiarticular chronic tophaceous gout with severe and multiple ulcerations: a case report.
25. Chronic kidney disease in gout in a managed care setting.
26. Gout: past, present, and future.
27. Chronic tophaceous gout.
28. The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity.
29. Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma.
30. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population.
31. Revisiting the pathogenesis of podagra: why does gout target the foot?
32. Monosodium urate monohydrate crystal-recruited noninflammatory monocytes differentiate into M1-like proinflammatory macrophages in a peritoneal murine model of gout.
33. Lack of association of -607 C/A and -137 G/C polymorphisms in interleukin 18 gene with susceptibility to gout disease in Chinese Han male population.
34. Osteoblast retraction induced by adherent neutrophils promotes osteoclast bone resorption: implication for altered bone remodeling in chronic gout.
35. Minimally important differences of the gout impact scale in a randomized controlled trial.
36. Contemporary epidemiology of gout in the UK general population.
37. Gout and chronic kidney disease.
38. Determinants of vascular function in patients with chronic gout.
39. MSU crystal-recruited non-inflammatory monocytes differentiate into M1-like pro-inflammatory macrophages in a peritoneal murine model of gout.
40. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
41. Multimodality imaging of chronic tophaceous gout.
42. Compliance in gout patients.
43. Application of dual-energy computed tomography for detecting uric acid deposition in patients with gout.
44. Epidemiology of gout.
45. Large epidemiologic studies of gout: challenges in diagnosis and diagnostic criteria.
46. Did The Captain only have gout?
47. Managing gout: how is it different in patients with chronic kidney disease?
48. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout.
49. Uncommon feature of gout effecting the spine.
50. New advances in the treatment of gout: review of pegloticase.
51. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts.
52. Fructose-rich beverages and risk of gout in women.
53. Monoarticular gout: cytological diagnosis.
54. Gout and its comorbidities.
55. Advances in gout: some answers, more questions.
56. Cervical arthropathy caused by gout: stabilisation without decompression.
57. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors.
58. Gout: a clinical syndrome illustrated and discussed.
59. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets.
60. Health care utilization in patients with gout.
61. Coffee consumption and risk of incident gout in women: the Nurses' Health Study.
62. Clinical images: Divergent patterns of joint remodeling following effective urate-lowering therapy in tophaceous gout.
63. Gout tophi with an atypical location in a patient with multiple septic gout tophi.
64. Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout.
65. Patients and providers view gout differently: a qualitative study.
66. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
67. Tophi as first manifestation of gout.
68. Erosive spinal tophus in a patient with gout and back pain.
69. Ultrasonographic signs of gout in symmetric polyarthritis.
70. Nurse-led cardiovascular disease risk management intervention for patients with gout.
71. Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer?
72. Sonographic description and classification of tendinous involvement in relation to tophi in chronic tophaceous gout.
73. Impact of diabetes against the future risk of developing gout.
74. Lucent lesions of the spine--a case of spinal gout.
75. Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion.
76. Expression and function of CXCL16 in a novel model of gout.
77. Images in rheumatology. Gout arthropathy.
78. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
79. Mechanisms of inflammation in gout.
80. Comment on: Gout: an independent risk factor for all-cause and cardiovascular mortality.
81. Semiological profile of gout in patients with AA, AS and AC hemoglobins.
82. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
83. Behavioral choice across leech species: chacun à son goût.
84. Pes anserine bursitis - an extra-articular manifestation of gout.
85. Dual-energy CT as a potential new diagnostic tool in the management of gout in the acute setting.
86. A national survey of Veterans Affairs rheumatologists for relevance of quality of care indicators for gout management.
87. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout.
88. Gout disease-specific quality of life and the association with gout characteristics.
89. Clinical images: gout revealed on arthroscopy after minor injury.
90. Comment on: An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs.
91. Management of hyperuricemia in gout: focus on febuxostat.
92. Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort.
93. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.
94. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study.
95. The dynamics of chronic gout treatment: medication gaps and return to therapy.
96. "Clinical features of women with gout arthritis." A systematic review.
97. Chronic tophaceous gout with severe deforming arthritis.
98. Serum cystatin C is a potential endogenous marker for the estimation of renal function in male gout patients with renal impairment.
99. Spinal gout mimicking paraspinal abscess: A case report.
100. Can gout mimic a soft tissue tumour?
101. New and improved strategies for the treatment of gout.
102. Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.
103. Political gout: dissolute patients, deceitful physicians, and other blue devils.
104. Taking the stress out of managing gout.
105. Gout: an independent risk factor for all-cause and cardiovascular mortality.
106. Prescription and comorbidity screening following consultation for acute gout in primary care.
107. Comment on: new insights into the epidemiology of gout.
108. Treating to target: a strategy to cure gout.
109. New insights into the epidemiology of gout.
110. Febuxostat: a new treatment for hyperuricaemia in gout.
111. Can we make gout crystal clear? Introduction.
112. Tophaceous gout with congenital dyserythropoietic anemia.
113. Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease.
114. Rheumatic diseases at the court of the Medici of Florence: the so-called "gout" of the Medici.
115. Influence of the natural history of disease on a previous diagnosis in patients with gout.
116. Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Māori, Pacific Island, and Caucasian case-control sample sets.
117. Inhibiting cyclooxygenase and 5-lipoxygenase activities is an anti-inflammatory mechanism of Huzhang Gout Granule.
118. Rasburicase for tophaceus gout treatment.
119. Recent insights into the pathogenesis of hyperuricaemia and gout.
120. The modern management of gout.
121. Gout--current diagnosis and treatment.
122. Tophi as an initial manifestation of gout.
123. An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs.
124. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
125. Whitish bullae on the fingers: what is the diagnosis? Tophaceous gout.
126. Case of anakinra as a steroid-sparing agent for gout inflammation.
127. Gout. Novel therapies for treatment of gout and hyperuricemia.
128. Cystic swelling of the acromioclavicular joint: an unusual complication of gout.
129. Lower back pain caused by tophaceous gout of the spine.
130. Menopause, postmenopausal hormone use and risk of incident gout.
131. Imaging of gout: findings and utility.
132. Chronic tophaceous gout: An uncommon localization.
133. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
134. Clinical images: Pseudorheumatoid gout.
135. Comment on: The 'gout' of the Medici, Grand Dukes of Florence: a palaeopathological study.
136. Acute gout during treatment with paclitaxel for metastatic melanoma.
137. Clinical images: Gout attack and stiff knee in an airline passenger in economy class.
138. Measurement of health-related quality of life and functional capacity in patients with chronic tophaceous gout.
139. Clinical features of gout in a cohort of Italian patients.
140. Thoracic spinal gout mimicking metastasis.
141. Reassessing serum urate targets in the management of refractory gout: can you go too low?
142. Febuxostat in the management of hyperuricemia and chronic gout: a review.
143. Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping.
144. Adherence with urate-lowering therapies for the treatment of gout.
145. Perceptions of disease and health-related quality of life among patients with gout.
146. Sleep apnea as a cause of gout flares.
147. Sleep apnea and gout.
148. Vitamin C intake and the risk of gout in men: a prospective study.
149. Elastic liposomal formulation for sustained delivery of colchicine: in vitro characterization and in vivo evaluation of anti-gout activity.
150. The 'gout' of the Medici, Grand Dukes of Florence: a palaeopathological study.
151. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
152. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout.
153. Clinical Images: Lumbar spondylolisthesis caused by tophaceous gout.
154. Generalised chronic tophaceous gout.
155. Inflammatory sciatica due to spinal tophaceous gout.
156. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.
157. NALP3 inflammasome functional polymorphisms and gout susceptibility.
158. Coexisting gout, erythrodermic psoriasis and psoriatic arthritis.
159. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
160. Prednisolone and naproxen both work for pain relief in acute gout.
161. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
162. Gout management: let's get it right this time.
163. Gout and the risk of Parkinson's disease: a cohort study.
164. Developments in the scientific and clinical understanding of gout.
165. Update on the management of hyperuricemia and gout.
166. Chronic tophaceous gout presenting as acute arthritis during an acute illness: a case report.
167. Early onset of hyperuricaemia and gout following treatment for female to male gender reassignment.
168. Acute gout: oral steroids work as well as NSAIDs.
169. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.
170. Treatment of Gout: Reflections From the GEMA Study.
171. The gout diagnosis.
172. The role of hyperuricemia and gout in kidney and cardiovascular disease.
173. Clinical manifestations of hyperuricemia and gout.
174. The pathogenesis of gout.
175. The practical management of gout.
176. Epidemiology of gout.
177. Confessions of a goutophile: Despite its treatability, gout remains a problem.
178. Hyperuricemia, gout, and lifestyle factors.
179. Atypical triggering at the wrist due to intratendinous infiltration of tophaceous gout.
180. Tophaceous gout of the lumbar spine simulating spondylodiscitis: imaging features: a case report.
181. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
182. Treatment-failure gout: a moving target.
183. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile.
184. Consider gout in patients with risk factors, regardless of age.
185. Symptomatic hypercalcemia in a patient with chronic tophaceous gout: a case report.
186. Tophaceous gout and rheumatoid arthritis awareness.
187. Probenecid, a gout remedy, inhibits pannexin 1 channels.
188. Gout in the spotlight.
189. Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells.
190. Association of incident gout and mortality in dialysis patients.
191. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men.
192. Validation of the Health Assessment Questionnaire disability index in patients with gout.
193. Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study.
194. Associations between gout tophus and polymorphisms 869T/C and -509C/T in transforming growth factor beta1 gene.
195. Gout and nodal osteoarthritis: a case-control study.
196. Disease-related and all-cause health care costs of elderly patients with gout.
197. Widespread arterial calcification in a patient with gout.
198. Management of recurrent gout: Professional guidelines differ.
199. Advanced gout.
200. Management of recurrent gout.
201. Sugary drinks, fruit, and increased risk of gout.
202. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study.
203. Tophaceous gout in a patient with rheumatoid arthritis.
204. Gout.
205. Diagnostic dilemmas in unusual presentations of gout.
206. International survey on the diagnosis and management of gout.
207. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra.
208. Tophaceous joint disease strongly predicts hand function in patients with gout.
209. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.
210. The polymorphism -863C/A in tumour necrosis factor-alpha gene contributes an independent association to gout.
211. Learning how and when to employ uricase as bridge therapy in refractory gout.
212. An unusual case of gout in the wrist: the importance of monitoring medication dosage and interaction. A case report.
213. Hyperuricemia and gout: new insights into pathogenesis and treatment.
214. Multiple asymptomatic nodules in a middle-aged patient. Tophaceous gout.
215. Information from your family doctor. Gout: what you should know.
216. Gout: an update.
217. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?
218. The role of interleukin-1 and the inflammasome in gout: implications for therapy.
219. Why is gout so poorly managed?
220. Independent impact of gout on mortality and risk for coronary heart disease.
221. Validation of a radiographic damage index in chronic gout.
222. Clinical image: Dual-energy computed tomographic molecular imaging of gout.
223. Homozygous frameshift mutation in the SLC22A12 gene in a patient with primary gout and high levels of serum uric acid.
224. Assessment of outcome in clinical trials of gout--a review of current measures.
225. Colchicine--what is its place in the management of acute gout?
226. Is gout associated with reduced quality of life? A case-control study.
227. Quality of care for gout in the US needs improvement.
228. Coffee consumption and risk of incident gout in men: a prospective study.
229. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.
230. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.
231. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.
232. Diagnosis of gout by ultrasound.
233. Gout in Valchiavenna in the XVII century: a case report.
234. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
235. A pilot study of IL-1 inhibition by anakinra in acute gout.
236. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
237. Are joints affected by gout also affected by osteoarthritis?
238. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey.
239. Validity of gout diagnoses in administrative data.
240. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.
241. Clinical images: three-dimensional computed tomography imaging of tophaceous gout.
242. High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study.
243. Gout in 2006: the perfect storm.
244. MR features of vertebral tophaceous gout.
245. Gout, have we met before? No, not like this...
246. The severe gout of Emperor Charles V.
247. The management of gout: it should be crystal clear.
248. Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils.
249. An unusual presentation of polyarticular tophaceous gout.
250. Chronic tophaceous gout of the third flexor digitorum profundus tendon in the hand: an unusual sonography diagnosis.
251. Effect of fenofibrate in combination with urate lowering agents in patients with gout.
252. Gout: new insights into an old disease.
253. Gout and the risk of acute myocardial infarction.
254. Gout, diuretics and the kidney.
255. Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout.
256. The inflammatory process of gout and its treatment.
257. Epidemiology, risk factors, and lifestyle modifications for gout.
258. A concise history of gout and hyperuricemia and their treatment.
259. Spinal cord compression by tophaceous gout with fluorodeoxyglucose-positron-emission tomographic/MR fusion imaging.
260. Diagnosis and management of gout.
261. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
262. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
263. Sex differences in gout epidemiology: evaluation and treatment.
264. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review.
265. Febuxostat versus allopurinol for gout.
266. Clinical image: corneal tophus deposition in gout.
267. The prevalence of metabolic syndrome in patients with gout: a multicenter study.
268. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
269. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
270. Images in clinical medicine. Deforming gout.
271. Tophaceous gout of the symphysis pubis.
272. Clinical, humanistic, and economic outcomes of gout.
273. Understanding treatments for gout.
274. Diagnosis of gout: clinical, laboratory, and radiologic findings.
275. Epidemiology of hyperuricemia and gout.
276. Gout, not induced by diuretics? A case-control study from primary care.
277. Diagnosis and management of gout: a rational approach.
278. Tophaceous gout causing atlanto-axial subluxation mimicking rheumatoid arthritis: a case report.
279. Tophaceous gout in the bipartite patella with intra-osseous and intra-articular lesions: a case report.
280. Purine metabolites in gout and asymptomatic hyperuricemia: analysis by HPLC-electrospray tandem mass spectrometry.
281. A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout.
282. Mechanisms of inflammation in gout.
283. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).
284. Gout: excess calories, purines, and alcohol intake and beyond. Response to a urate-lowering diet.
285. Running for gout research.
286. Renal function in minahasanese patients with chronic gout arthritis and tophi.
287. Case number 33: about being a famous European and suffering from gout.....
288. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
289. A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?
290. Urate oxidase (rasburicase) for treatment of severe tophaceous gout.
291. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.
292. Concomitant gout and rheumatoid arthritis--a case report.
293. Acute gout attack in the wrist joint.
294. Gout: on the brink of novel therapeutic options for an ancient disease.
295. Gout: a review of its aetiology and treatment.
296. Gout and alcohol.
297. A (very) short history of diets for gout.
298. Genomewide scan for gout in taiwanese aborigines reveals linkage to chromosome 4q25.
299. Gout in liver transplant patients receiving tacrolimus.
300. Tophaceous gout of the pubic symphysis: an unusual cause of groin pain.
301. Purine-rich foods and the risk of gout in men.
302. Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout.
303. "Like a virgin": Absence of rheumatoid arthritis and treponematosis, good sanitation and only rare gout in Italy prior to the 15th century.
304. Mucinous adenocarcinoma of the renal pelvis associated with lithiasis and chronic gout.
305. Quality of care indicators for gout management.
306. Purine-rich foods, dairy and protein intake, and the risk of gout in men.
307. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
308. Colchicine in acute gout: low dose colchicine was started after usual dose.
309. Colchicine in acute gout: optimal dose of colchicine is still elusive.
310. Gout.
311. Complex segregation and linkage analysis of familial gout in Taiwanese aborigines.
312. Gout complicated with necrotizing fasciitis--report of 15 cases.
313. Case report: MRI findings in gout.
314. Colchicine in acute gout.
315. A case-control study of the association of diet and obesity with gout in Taiwan.
316. Sonographic monitoring of gout.
317. Trends in the manifestations of gout in Taiwan.
318. Hyperuricemia and gout among Taiwan Aborigines and Taiwanese-prevalence and risk factors.
319. Gout, just a nasty event or a cardiovascular signal? A study from primary care.
320. Primary gout in Shantou: a clinical and epidemiological study.
321. The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates.
322. Management of hyperuricemia in occupational health: with reference to "guidelines for the management of hyperuricemia and gout".
323. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
324. "Gout and the spider" by Jean de La Fontaine (1621-1695), or the metamorphoses of a rheumatology tale.
325. Younger age of onset of gout in Taiwan.
326. Update on gout.
327. Cushing's syndrome caused by treatment of gout with traditional Chinese medicine.
328. The crystal, the gout, and the paradox.
329. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
330. Hyperuricemia and gout: a reign of complacency.
331. Total plasma homocysteine is not increased in Japanese patients with gout.
332. Gout, diet, and the insulin resistance syndrome.
333. Interactions between leukocytes and endothelial cells in gout: lessons from a self-limiting inflammatory response.
334. Gout and kidney during XVII and XIX centuries.
335. Imaging of tophaceous gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography.
336. Acromioclavicular cyst and 'porcupine shoulder' in gout.
337. Fenofibrate: a new treatment for hyperuricaemia and gout?
338. Relation between adverse events associated with allopurinol and renal function in patients with gout.
339. Evaluation of crystals in formalin-fixed, paraffin-embedded tissue sections for the differential diagnosis of pseudogout, gout, and tumoral calcinosis.
340. Spinal cord compression: an unusual neurological complication of gout.
341. Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout.
342. Carpal tunnel syndrome caused by tophaceous gout: CT and MR imaging features in 20 patients.
343. Noninflammatory phagocytosis of monosodium urate monohydrate crystals by mouse macrophages. Implications for the control of joint inflammation in gout.
344. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study.
345. Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients?
346. Use of intravenous colchicine in patients with acute gout.
347. Renal transplant-associated hyperuricemia and gout.
348. Localization of a gene for familial juvenile hyperuricemic nephropathy causing underexcretion-type gout to 16p12 by genome-wide linkage analysis of a large family.
349. Gout. Easy to misdiagnose.
350. Gout.
351. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity.
352. Diagnosis and management of gout.
353. Gout and hyperuricemia.
354. Gout: the patrician malady
355. Low-back pain caused by spinal tophus--a complication of gout in a kidney transplant recipient.
356. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
357. Hyperlipidaemia in hyperuricaemia and gout.
358. Serum uric acid in acute gout.
359. Vertebral erosion, paraplegia, and spinal gout.
360. Orderly arrayed deposit of urate crystals in gout suggest epitaxial formation.
361. The epidemiology of hyperuricaemia and gout in Taiwan aborigines.
362. Analysis of abnormalities in purine metabolism leading to gout and to neurological dysfunctions in man.
363. Serum uric acid in acute gout.
364. Gout due to xanthine derivatives.
365. Omeprazole, other antiulcer drugs and newly diagnosed gout.
366. High prevalence of hyperuricaemia among Kuwaitis possibly without a proportionate increase in gout.
367. MR imaging of tophaceous gout.
368. Gout is on the increase in New Zealand.
369. Enthesopathy and tendinopathy in gout: computed tomographic assessment.
370. Treatment of gout following cardiac transplantation.
371. Gout: the last 50 years.
372. Tophaceous gout of the lumbar spine mimicking an epidural abscess: MR features.
373. Down syndrome with coexistent gout: report of six patients and possible reasons for the scarcity of descriptions of this association.
374. Gout, uric acid, albumin, and aging.
375. Rheumatoid arthritis preceding the onset of polyarticular tophaceous gout.
376. Management of gout.
377. Characterization of E-selectin expression, leucocyte traffic and clinical sequelae in urate crystal-induced inflammation: an insight into gout.
378. The diagnosis of gout and CPPD crystal arthropathy.
379. Gout in the cervical spine: MR pattern mimicking diskovertebral infection.
380. Development of a 'Charcot-like joint' in tophaceous gout.
381. Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia.
382. Images in clinical medicine. Tophaceous gout.
383. ABC of rheumatology. Gout, hyperuricaemia, and crystal arthritis.
384. Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout.
385. Missed opportunity following diagnosis of gout.
386. Gout: questions that still need to be answered.
387. Gout in black South Africans: a clinical and genetic study.
388. Towards a coherent terminology of gout.
389. William Stukeley and the gout.
390. Diuretic induced gout: a multifactorial condition.
391. Increased serum cytidine deaminase activity in gout and articular chondrocalcinosis.
392. Investigation and management of gout in the young and the elderly.
393. Arthrodesis for recurrent manubriosternal gout.
394. Image interpretation session. Intraosseous gout.
395. Gout and neurological abnormalities associated with cardiomyopathy in a young man.
396. Fructose-induced aberration of metabolism in familial gout identified by 31P magnetic resonance spectroscopy.
397. Cyclosporine-induced hyperuricemia and gout.
398. Alcohol and gout.
399. Diuretic-induced gout.
400. Intervertebral disc involvement in gout: brief report.
401. Alcohol and response to treatment of gout.
402. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia.
403. Migration and gout: the Tokelau Island migrant study.
404. Visceral gout in a rough legged hawk (Buteo lagopus).
405. Gout in the elderly, a separate entity?
406. Effect of treatment on erythrocyte phosphoribosyl pyrophosphate synthetase and glutathione reductase activity in patients with primary gout.
407. Hyperlipoproteinaemia in primary gout: hyperlipoproteinaemic phenotype and influence of alcohol intake and obesity in Japan.
408. Samuel Johnson's gout.
409. Demonstration of an abnormality of C apoprotein of very low density lipoprotein in patients with gout.
410. Studies on the interaction of rheumatoid factor with monosodium urate crystals and case report of coexistent tophaceous gout and rheumatoid arthritis.
411. Hyperuricemia and gout.
412. Irregular gout: humoral fantasy or saturnine malady.
413. A case-control study of alcohol consumption and drinking behaviour in patients with acute gout.
414. Crystal deposition in the knee and great toe joints of asymptomatic gout patients.
415. Gout in South African blacks.
416. Acute gout and the accident and emergency department.
417. William Harvey and his gout.
418. Hypoxanthine guanine phosphoribosyl transferase deficiency presenting with gout and renal failure in infancy.
419. Studies of urate crystallisation in relation to gout.
420. Gout.
421. Food, drink, and gout.
422. Spondylodiscal erosions due to gout: anatomico-radiological study of a case.
423. Vascular mortality in patients with gout and in their families.
424. A controlled study of diet in patients with gout.
425. Acute polyarticular gout.
426. Human hypoxanthine (guanine) phosphoribosyltransferase: an amino acid substitution in a mutant form of the enzyme isolated from a patient with gout.
427. Purine oversecretion in cultured murine lymphoma cells deficient in adenylosuccinate synthetase: genetic model for inherited hyperuricemia and gout.
428. Psoriasis and gout.
429. Allopurinol effect on renal function in gout.
430. Family study of lipid and purine levels in gout patients.
431. Allopurinol treatment and its effect on renal function in gout: a controlled study.
432. Intraosseous calcifications in tophaceous gout.
433. Uric acid, gout and the kidney.
434. Familial gout and renal failure.
435. Coexistent rheumatoid arthritis and tophaceous gout: a case report.
436. Spontaneous rupture of the Achilles tendon in a patient with gout.
437. Gout in haemoglobinopathies.
438. Gout and amyloidosis.
439. Long-term management of gout and hyperuricaemia.
440. Acute gout during hypouricaemic therapy: prophylaxis with colchicine.
441. Gout secondary to chronic renal disease: studies on urate metabolism.
442. Renal impairment and gout.
443. Controlled inpatient study of tienilic acid in treatment of gout and hypertension.
444. A radiologic reevaluation of gout: a study of 2,000 patients.
445. Frequency of chondrocalcinosis of the knees and avascular necrosis of the femoral heads in gout: a controlled study.
446. Gout and port.
447. Gout.
448. Prevalence and incidence of the diagnosis of gout in Great Britain.
449. Secondary hypertriglyceridemia and hyperlipoproteinemia in patients with primary asymptomatic gout.
450. Mechanism and treatment of hypertriglyceridaemia in gout.
451. The pathology of nephrotoxicity of gentamicin in snakes. A model for reptilian gout.
452. Subclinical lead exposure: a possible cause of gout.
453. A prospective study of gout in New Zealand Maoris.
454. High prevalence of hyperuricaemia and gout in an urbanised Micronesian population.
455. Gout without crystals on initial synovial fluid analysis.
456. New knowledge of the pathogenesis of gout.
457. Pathologic fractures in an unusual case of gout.
458. The cartoon in doctor-patient communication. Further study of the Arthritis and Rheumatism Council handbook on gout.
459. Therapeutic test with colchicine in diagnosis of gout.
460. Lack of effect of two pectins in idiopathic or gout-associated hyperdyslipidemia hypercholesterolemia.
461. Gout with normal serum urate concentration.
462. Multicentre trial of naproxen and phenylbutazone in acute gout.
463. Bullous tophi in gout.
464. Sparing effect of hemiplegia on tophaceous gout.
465. Acute renal failure and gout as presenting features of acute lymphoblastic leukaemia.
466. Acute myelomonocytic leukaemia and multiple myeloma after sulphinpyrazone and colchicine treatment of gout.
467. Gout induced by L-dopa and decarboxylase inhibitors.
468. Letter: Primary gout affecting the sternoclavicular joint.
469. Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction.
470. Primary gout affecting the sternoclavicular joint.
471. Lesions resembling gout in patients with rheumatoid arthritis.
472. Hypoxanthine-guanine phosphoribosyltransferase. Characterization of a mutant in a patient with gout.
473. Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts.
474. Letter: Drug-precipitated acute attacks of gout.
475. Letter: From a gout sufferer.
476. Abnormal regulation of carbohydrate metabolism in primary gout.
477. Withdrawal of allopurinol in patients with gout.
478. Gout and hyperlipidaemia.
479. Letter: Treatment of acute gout.
480. Letter: Treatment of acute gout.
481. Gout.
482. Visceral gout and amyloidosis in a mute swan (Cygnus olor).
483. Proceedings: Gout, hypertriglyceridaemia, and alcohol consumption.
484. Gout and its relation to lipid metabolism. II. Correlations between uric acid, lipid, and lipoprotein levels in gout.
485. Gout and its relation to lipid metabolism. I. Serum uric acid, lipid, and lipoprotein levels in gout.
486. The kinetics of intramolecular distribution of 15N in uric acid after administration of (15N) glycine. A reappraisal of the significance of preferential labeling of N-(3+9) of uric acid in primary gout.
487. Human phosphoribosylpyrophosphate synthetase: increased enzyme specific activity in a family with gout and excessive purine synthesis.
488. Comparison of indomethacin and phenylbutazone in acute gout.
489. Steatorrhoea and jejunal reticulum cell sarcoma occurring in a patient on long-term colchicine therapy for gout.
490. Platelet adhesiveness in gout.
491. A reappraisal of the concept of an abnormality of glutamine metabolism in primary gout.
492. Plasma lipid levels in gout.
493. Diagnosis of gout.
494. Evaluation of the Arthritis and Rheumatism Council Handbook on Gout. An objective study of doctor-patient communication.
495. Gout in a New England town. A prevalence study in Sudbury, Massachusetts.
496. Organic acid excretion patterns in gout.
497. Psychosomatic considerations in hyperuricemia and gout.
498. IgG antiglobulin levels in patients with psoriatic arthropathy, ankylosing spondylitis, and gout.
499. Juvenile gout.
500. Plasma lipid levels and platelet adhesiveness in gout.
501. Bilateral spontaneous and simultaneous rupture of the quadriceps tendons in gout.
502. An unusual form of renal disease associated with gout and hypertension.
503. Uric acid clearance in patients with gout and normal subjects.
504. Juvenile gout.
505. Hyperlipoproteinaemia in gout.
506. Hereditary susceptibility to dietary induction of gout in selected lines of chickens.
507. Phosphoribosyl transferase activity in normal subjects, gout patients, and children with mental retardation.
508. Xanthomatosis, hyperlipoproteinaemia (type II, Fredrickson), gout, cardiac infarction.
509. Serum protein changes in Still's disease, rheumatoid arthritis and gout.
510. Clinical survey of 354 patients with gout.
511. Uric acid excretion in the relatives of patients with gout.
512. Retrospective clinical survey of 354 cases of gout.
513. Epidemiology of serum uric acid and gout: an example of the complexities of multifactorial causation.
514. Gout: current concepts and treatment.
515. Long-term use of allopurinol in the treatment of gout.
516. Pathophysiology of hyperuricemia in primary gout.
517. Gout.
518. Nail changes in gout.
519. Management of gout.
520. Dietes mellitus and gout. Blood sugar and plasma insulin responses to oral glucose in normal weight, overweight, and gouty patients.
521. The first medical monograph on the gout.
522. Plasma and urinary amino acids in primary gout, with special reference to glutamine.
523. Total fasting, hyperuricaemia and gout.
524. Gout and hyperuricemia.
525. Current concepts of hyperuricemia and gout.
526. Difficult case of gout.
527. The role of fundamental biochemical research in medicine, as exemplified by gout.
528. Pyrazolidines in the treatment of gout.
529. Nyhan-Lesch syndrome and juvenile gout (2 cases).
530. Gout and uveitis. Report of a case.
531. Variations in purine metabolism of cultured skin fibroblasts from patients with gout.
532. Genetic studies in primary gout. Investigations on the plasma levels of the urate-binding alpha 1-alpha 2-globulin in individuals from two gouty kindreds.
533. Gout.
534. St. Wolfgang and gout.
535. Bony ankylosis in gout.
536. Sulphobromophthalein retention in gout and asymptomatic hyperuricaemia.
537. Diet and alcohol in gout.
538. A specific enzyme defect in gout associated with overproduction of uric acid.
539. Allopurinol in the treatment of uraemic patients with gout.
540. Gout and diabetes mellitus.
541. The treatment of gout and disorders of uric acid metabolism with allopurinol.
542. Psychiatric observations on attacks of gout in a patient with ulcerative colitis. Report of a case.
543. Allopurinol therapy of gout with renal complications.
544. Allopurinol in primary gout with and after the administration of uricosuric agents.
545. Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone.
546. Treatment of gout with allopurinol. A study of 106 cases.
547. Biochemical considerations of the renal damage of gout.
548. Gout and gouty arthritis. Current concepts and management.
549. Allopurinol for gout.
550. Allopurinol in treatment of gout.
551. Treatment of gout by reduction of uric acid production.
552. Acute gout apparently precipitated by furosemide.
553. Sacro-iliac gout.
554. Lipid metabolism in gout.
555. Hyperuricaemia and gout in the Mariana Islands.
556. Suppression of the shunt pathway in primary gout by azathioprine.
557. Effect of atromid and its components on uric acid excretion and on gout.
558. Significance of joint fluid uric acid levels in gout.
559. URINARY AMMONIUM EXCRETION IN PRIMARY GOUT.
560. SYNOVIAL FLUID IN GOUT.
561. Gout with Hyperparathyroidism: Report of Case with Examination of Synovial Fluid.
562. MALIGNANT GOUT WITH TOPHACEOUS SMALL INTESTINE AND MEGALOBLASTIC ANAEMIA.
563. A EUNUCH TAKES THE GOUT.
564. ALLOPURINOL IN GOUT.
565. The Prevention of Gout.
566. TO-DAY'S DRUGS. DRUGS IN THE TREATMENT OF GOUT.
567. 4-HYDROXYPYRAZOLO (3,4-D) PYRIMIDINE (HPP) IN THE TREATMENT OF GOUT: PRELIMINARY OBSERVATIONS.
568. ASSOCIATION OF HYPERURICAEMIA AND GOUT WITH HYPERPARATHYROIDISM.
569. DRUGS FOR GOUT.
570. BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT.
571. CHANGES IN SERUM AND URINARY URIC ACID WITH THE DEVELOPMENT OF SYMPTOMATIC GOUT.
572. INFLAMMATORY POLYARTHRITIC DISEASE. IV. GOUT.
573. The Kidneys in Gout.
574. Gout in the time and person of George IV: a case history.
575. IMPAIRMENT OF URIC ACID EXCRETION IN GOUT.
576. Gout, Steatorrhoea, and Megaloblastic Anaemia.
577. Gout, Megaloblastic Anaemia and Steatorrhoea.
578. Gout and hyperuricaemia in rural and urban populations.
579. THE RENAL EXCRETION OF URIC ACID IN GOUT.
580. Gout in a general practice.
581. A non-articular manifestation of gout.
582. Lack of Correlation Between Gout and the Incorporation of Isotopic Formate into Uric Acid.
583. Uric acid production in gout.
584. Renal biopsy in gout.
585. Gout and the haemoglobin level in patients with cardiac and respiratory disease.
586. Gout from cyanotic congenital heart disease.
587. Gout in cyanotic congenital heart disease.
588. The renal factor in the etiology of primary gout.
589. New Uricosuric Agent in the Treatment of Gout: para-Carboxybenzenesulpha-diethylamide (Urelim).
590. Uricosuric agents in the treatment of gout.
591. Gout as a complication of chlorothiazide therapy.
592. Gout and Cerebral Palsy in a Three-year-old Boy.
593. Gout in the Maori.
594. Sarcoidosis, psoriasis, and gout: syndrome or coincidence?
595. The renal excretion of uric acid in patients with gout and in nongouty subjects.
596. Drug treatment of gout.
597. Tophaceous gout in a 17-year-old male.
598. Value of uricosuric agents and in particular of G. 28 315 in gout.
599. Atypical manifestations of gout.
600. On the mechanism of overproduction of uric acid in patients with primary gout.